Celularity Form 4: Director Diane Parks granted 61,539 RSUs

Rhea-AI Filing Summary

Celularity Inc. (CELU) reported an equity award to a director. Director Diane Parks received 61,539 restricted stock units (RSUs) of Class A common stock on 11/19/2025 under the Celularity Inc. 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of Class A common stock, and the RSUs vest and become exercisable on the grant date at a price of $0.00 per share. Following this grant, Diane Parks beneficially owns 365,021 shares of Celularity Class A common stock in direct ownership.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Parks Diane L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	61,539	$0.00	--

Holdings After Transaction: Class A Common Stock — 365,021 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parks Diane L.

(Last) (First) (Middle)

C/O CELULARITY INC.

170 PARK AVENUE

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Celularity Inc [ CELU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/19/2025		A		61,539(1)	A	$0.00	365,021	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the date of grant.

	/s/ Diane Parks	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Celularity Inc. (CELU) disclose in this Form 4 filing?

The filing reports that director Diane Parks received 61,539 RSUs of Celularity Inc. Class A common stock on 11/19/2025 under the company’s 2021 Equity Incentive Plan.

How many Celularity (CELU) shares does Diane Parks own after this transaction?

After the reported grant, Diane Parks beneficially owns 365,021 shares of Celularity Inc. Class A common stock in direct ownership.

What are the terms of the RSUs granted to the Celularity director?

The 61,539 RSUs each represent a right to receive one share of Class A common stock and, according to the disclosure, vest and become exercisable on the date of grant at a price of $0.00 per share.

Under which plan were the Celularity (CELU) RSUs granted?

The restricted stock units were granted under the Celularity Inc. 2021 Equity Incentive Plan, which is used to issue equity awards to eligible participants.

What is Diane Parks’ relationship to Celularity Inc. (CELU)?

Diane Parks is identified in the filing as a Director of Celularity Inc., and the Form 4 is filed as a report by one reporting person.

Was this Celularity (CELU) Form 4 linked to a Rule 10b5-1 trading plan?

The form includes a checkbox for indicating transactions made under a Rule 10b5-1(c) plan, but the content provided does not show that this grant was reported as such; it is presented as an equity award grant.